Chemotherapy with the use of next‐generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

医学 内科学 危险系数 造血干细胞移植 肿瘤科 移植 微小残留病 化疗 伊马替尼 人口 白血病 外科 置信区间 髓系白血病 环境卫生
作者
Mixue Xie,Ting Shi,Qi Jiang,Yunlu Jia,De Zhou,Hongyan Tong,Jie Jin,Hong‐Hu Zhu
出处
期刊:Cancer [Wiley]
卷期号:129 (10): 1523-1536 被引量:3
标识
DOI:10.1002/cncr.34710
摘要

Abstract Background Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) as postremission treatment is recommended for Philadelphia‐positive acute lymphoblastic leukemia (Ph+ ALL) in current guidelines. However, comparisons of later generation tyrosine kinase inhibitors (TKIs) plus chemotherapy with allo‐HSCT have yielded similar outcomes. This meta‐analysis was performed to evaluate allo‐HSCT in first complete remission (CR1) versus chemotherapy for adult Ph+ ALL in the TKI era. Methods Pooled assessment of the hematologic and molecular complete response rates was performed after 3‐month TKI treatment. Hazard ratios (HRs) were determined for disease‐free survival (DFS) and overall survival (OS) benefit with allo‐HSCT. The effect of measurable residual disease status on survival benefit was also analyzed. Results Thirty‐nine retrospective and prospective single‐arm cohort studies involving 5054 patients were included. Combined HRs indicated that in the general population, allo‐HSCT favorably influenced DFS and OS. Achieving complete molecular remission (CMR) within 3 months after starting induction was a favorable survival prognostic factor regardless of whether the patient had undergone allo‐HSCT. Among the patients with CMR, survival rates in the nontransplant subgroup were comparable with those in the transplant subgroup, with the estimated 5‐year OS of 64% versus 58% and 5‐year DFS of 58% versus 51%, respectively. The use of next‐generation TKIs results in a higher proportion of patients achieving CMR (ponatinib 82% vs. imatinib 53%), while improving survival in nontransplant patients. Conclusion Our novel findings suggest that combination chemotherapy plus TKIs leads to a comparable survival benefit as with allo‐HSCT for MRD‐negative (CMR) patients. This study provides novel evidence for allo‐HSCT indications for Ph+ ALL in CR1 in the TKI era.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
水牛完成签到,获得积分10
刚刚
刚刚
雪流星完成签到 ,获得积分10
2秒前
精明尔芙敏完成签到 ,获得积分10
5秒前
aaa完成签到,获得积分10
7秒前
开心的人杰完成签到,获得积分10
7秒前
神外王001完成签到 ,获得积分10
7秒前
兰亭序完成签到 ,获得积分10
8秒前
SSDlk完成签到,获得积分10
8秒前
11秒前
沉静的清涟完成签到,获得积分10
12秒前
啊啊啊啊啊啊啊完成签到,获得积分10
14秒前
15秒前
认真的半青完成签到 ,获得积分10
15秒前
Xu发布了新的文献求助10
16秒前
魔幻的惜灵完成签到 ,获得积分10
18秒前
完美幻桃完成签到,获得积分10
19秒前
解方程组完成签到,获得积分10
20秒前
任性星星完成签到 ,获得积分10
21秒前
power完成签到 ,获得积分10
21秒前
lx完成签到,获得积分10
21秒前
蔡琪发布了新的文献求助10
22秒前
怕孤单的以寒完成签到 ,获得积分10
22秒前
淡定又夏完成签到 ,获得积分10
23秒前
像风一样完成签到,获得积分10
26秒前
雷霆宝贝完成签到 ,获得积分10
27秒前
TT工作好认真完成签到 ,获得积分10
29秒前
整齐盼烟完成签到,获得积分10
29秒前
jadespring完成签到,获得积分10
30秒前
善良的觅荷完成签到,获得积分10
31秒前
早一点完成签到 ,获得积分10
32秒前
魁梧的傲安完成签到,获得积分10
32秒前
TGU的小马同学完成签到 ,获得积分10
33秒前
kyousan完成签到,获得积分10
35秒前
Hi完成签到,获得积分10
35秒前
小四完成签到,获得积分10
35秒前
诚心巧曼完成签到 ,获得积分10
36秒前
hadfunsix完成签到 ,获得积分10
38秒前
影像大侠完成签到,获得积分10
39秒前
贾贡献的应助被科研通管家采纳,获得20
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923